CDA | Evidence Driven
CDA | Evidence Driven

garadacimab

Details

Generic Name:
garadacimab
Project Status:
Pending
Therapeutic Area:
Hereditary angioedema (HAE)
Manufacturer:
CSL Behring Canada Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0860-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Routine prevention of attacks of hereditary angioedema (HAE) in adult and pediatric patients (aged 12 years and older).
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Routine prevention of attacks of hereditary angioedema (HAE) in adult and pediatric patients (aged 12 years and older).
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Last Updated : June 10, 2024